Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

corporate communications

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

Merck to pilot digital behavioural change programme

Will work with US digital therapeutics firm Blue Mesa Health in diabetes

- PMLiVE

Communiqué Awards 2018 are open for entry

This year the med comms programme adds two new categories

Lilly signs real-world digital diabetes deal with Livongo

Will work with the US consumer digital health firm on research collaboration

Alexa: find Novo Nordisk voice-activated diabetes tech

Hitlab challenge selects patient education firm Lighthouse for $50,000 funding

Lilly boosts its forthcoming diabetes digital health offering

Strikes diabetes deal with US software and analytics firm Rimidi

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

- PMLiVE

Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity

GLP-1 agonist Ozempic approved in the US for type 2 diabetes

Sanofi reception

Dupixent dulls pain of diabetes slump at Sanofi

Biosimilar competition caused steep declines in its flagship product Lantus

- PMLiVE

Dexcom and Fitbit team up to tackle diabetes management

Will develop a wearable blood glucose tracking product

- PMLiVE

AZ gets US green light for new Bydureon formulation

Its latest injectable suspension proven to reduce blood sugar levels

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links